FDA Anti-Infective Drugs Advisory Committee
Executive Summary
Syntex ganciclovir for cytomegalovirus in immune-compromised patients will be on committee's Oct. 26-27 meeting agenda. Panel's review of ganciclovir, initially scheduled for July 13, had been postponed at FDA's request to allow for further review of safety and efficiacy data.